Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography

Toru Udaka, Chiharu Torii, Daisuke Takahashi, Tetsuya Mori, Michihiko Aramaki, Rika Kosaki, Yusuke Tanigawara, Takao Takahashi, Kenjiro Kosaki

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The drug-metabolizing enzyme thiopurine S-methyltransferase (TPMT) catalyzes the S-methylation of thiopurines such as 6-mercaptopurine, 6-thioguanine, and azathiopurine, which are used as immunosuppressants and in the treatment of acute lymphoblastic leukemia and rheumatoid arthritis. TPMT enzymatic activity is a polymorphic trait, and poor metabolizers may develop life-threatening bone marrow failure. To avoid such adverse effects, the TPMT enzymatic activity in patients' red blood cells (RBCs) is routinely measured prior to thiopurine administration in a limited number of oncology clinics. In the present study, we took advantage of a highly sensitive and specific automated denaturing high-performance liquid chromatography (dHPLC) technique that not only detects known polymorphic alleles, but also identifies previously uncharacterized sequence variants. We developed a dHPLC-based protocol to analyze the entire coding region and validated the protocol to detect all 16 previously described variant alleles. We further analyzed the entire coding region of the TPMT gene in 288 control samples collected worldwide and identified two novel amino acid substitutions Arg163Cys (487C>T) and Arg226Gln (677G>A) within exons 7 and 10, respectively. The clinical application of this comprehensive screening system for examining the entire TPMT gene would help to identify patients at risk for bone marrow failure prior to 6-mercaptopurine therapy.

Original languageEnglish
Pages (from-to)85-92
Number of pages8
JournalGenetic Testing
Volume9
Issue number2
DOIs
Publication statusPublished - 2005 Jun

Fingerprint

thiopurine methyltransferase
High Pressure Liquid Chromatography
6-Mercaptopurine
Bone Marrow
Alleles
Thioguanine
Amino Acid Substitution
Immunosuppressive Agents
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methylation
Genes
Exons
Rheumatoid Arthritis
Erythrocytes
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography. / Udaka, Toru; Torii, Chiharu; Takahashi, Daisuke; Mori, Tetsuya; Aramaki, Michihiko; Kosaki, Rika; Tanigawara, Yusuke; Takahashi, Takao; Kosaki, Kenjiro.

In: Genetic Testing, Vol. 9, No. 2, 06.2005, p. 85-92.

Research output: Contribution to journalArticle

Udaka, Toru ; Torii, Chiharu ; Takahashi, Daisuke ; Mori, Tetsuya ; Aramaki, Michihiko ; Kosaki, Rika ; Tanigawara, Yusuke ; Takahashi, Takao ; Kosaki, Kenjiro. / Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography. In: Genetic Testing. 2005 ; Vol. 9, No. 2. pp. 85-92.
@article{b435aac03d1241a287763e4f44645018,
title = "Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography",
abstract = "The drug-metabolizing enzyme thiopurine S-methyltransferase (TPMT) catalyzes the S-methylation of thiopurines such as 6-mercaptopurine, 6-thioguanine, and azathiopurine, which are used as immunosuppressants and in the treatment of acute lymphoblastic leukemia and rheumatoid arthritis. TPMT enzymatic activity is a polymorphic trait, and poor metabolizers may develop life-threatening bone marrow failure. To avoid such adverse effects, the TPMT enzymatic activity in patients' red blood cells (RBCs) is routinely measured prior to thiopurine administration in a limited number of oncology clinics. In the present study, we took advantage of a highly sensitive and specific automated denaturing high-performance liquid chromatography (dHPLC) technique that not only detects known polymorphic alleles, but also identifies previously uncharacterized sequence variants. We developed a dHPLC-based protocol to analyze the entire coding region and validated the protocol to detect all 16 previously described variant alleles. We further analyzed the entire coding region of the TPMT gene in 288 control samples collected worldwide and identified two novel amino acid substitutions Arg163Cys (487C>T) and Arg226Gln (677G>A) within exons 7 and 10, respectively. The clinical application of this comprehensive screening system for examining the entire TPMT gene would help to identify patients at risk for bone marrow failure prior to 6-mercaptopurine therapy.",
author = "Toru Udaka and Chiharu Torii and Daisuke Takahashi and Tetsuya Mori and Michihiko Aramaki and Rika Kosaki and Yusuke Tanigawara and Takao Takahashi and Kenjiro Kosaki",
year = "2005",
month = "6",
doi = "10.1089/gte.2005.9.85",
language = "English",
volume = "9",
pages = "85--92",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography

AU - Udaka, Toru

AU - Torii, Chiharu

AU - Takahashi, Daisuke

AU - Mori, Tetsuya

AU - Aramaki, Michihiko

AU - Kosaki, Rika

AU - Tanigawara, Yusuke

AU - Takahashi, Takao

AU - Kosaki, Kenjiro

PY - 2005/6

Y1 - 2005/6

N2 - The drug-metabolizing enzyme thiopurine S-methyltransferase (TPMT) catalyzes the S-methylation of thiopurines such as 6-mercaptopurine, 6-thioguanine, and azathiopurine, which are used as immunosuppressants and in the treatment of acute lymphoblastic leukemia and rheumatoid arthritis. TPMT enzymatic activity is a polymorphic trait, and poor metabolizers may develop life-threatening bone marrow failure. To avoid such adverse effects, the TPMT enzymatic activity in patients' red blood cells (RBCs) is routinely measured prior to thiopurine administration in a limited number of oncology clinics. In the present study, we took advantage of a highly sensitive and specific automated denaturing high-performance liquid chromatography (dHPLC) technique that not only detects known polymorphic alleles, but also identifies previously uncharacterized sequence variants. We developed a dHPLC-based protocol to analyze the entire coding region and validated the protocol to detect all 16 previously described variant alleles. We further analyzed the entire coding region of the TPMT gene in 288 control samples collected worldwide and identified two novel amino acid substitutions Arg163Cys (487C>T) and Arg226Gln (677G>A) within exons 7 and 10, respectively. The clinical application of this comprehensive screening system for examining the entire TPMT gene would help to identify patients at risk for bone marrow failure prior to 6-mercaptopurine therapy.

AB - The drug-metabolizing enzyme thiopurine S-methyltransferase (TPMT) catalyzes the S-methylation of thiopurines such as 6-mercaptopurine, 6-thioguanine, and azathiopurine, which are used as immunosuppressants and in the treatment of acute lymphoblastic leukemia and rheumatoid arthritis. TPMT enzymatic activity is a polymorphic trait, and poor metabolizers may develop life-threatening bone marrow failure. To avoid such adverse effects, the TPMT enzymatic activity in patients' red blood cells (RBCs) is routinely measured prior to thiopurine administration in a limited number of oncology clinics. In the present study, we took advantage of a highly sensitive and specific automated denaturing high-performance liquid chromatography (dHPLC) technique that not only detects known polymorphic alleles, but also identifies previously uncharacterized sequence variants. We developed a dHPLC-based protocol to analyze the entire coding region and validated the protocol to detect all 16 previously described variant alleles. We further analyzed the entire coding region of the TPMT gene in 288 control samples collected worldwide and identified two novel amino acid substitutions Arg163Cys (487C>T) and Arg226Gln (677G>A) within exons 7 and 10, respectively. The clinical application of this comprehensive screening system for examining the entire TPMT gene would help to identify patients at risk for bone marrow failure prior to 6-mercaptopurine therapy.

UR - http://www.scopus.com/inward/record.url?scp=21044449130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044449130&partnerID=8YFLogxK

U2 - 10.1089/gte.2005.9.85

DO - 10.1089/gte.2005.9.85

M3 - Article

C2 - 15943548

AN - SCOPUS:21044449130

VL - 9

SP - 85

EP - 92

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 2

ER -